{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:21:00Z","timestamp":1790745660990,"version":"4.1.0"},"reference-count":0,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2001,12,25]],"date-time":"2001-12-25T00:00:00Z","timestamp":1009238400000},"content-version":"vor","delay-in-days":419,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2000,11]]},"abstract":"<jats:p>Abstract: <jats:italic>Aim<\/jats:italic>: Bisphosphonates are potent inhibitors of osteoclastic activity and are used in the treatment of multiple myeloma (MM) in combination with chemotherapy. The effect of pamidronate on markers of bone resorption [cross\u2010linked <jats:italic>N<\/jats:italic>\u2010telopeptides of type I collagen (NTx)], markers of bone formation [serum alkaline phosphatase (BAP) and osteocalcin (OSC)], interleukin\u20106 (IL\u20106), \u03b2<jats:sub>2<\/jats:sub>\u2010microglobulin, CRP, paraprotein and disease\u2010related pain and skeletal events has been evaluated in 62 newly diagnosed patients with MM. <jats:italic>Patients and methods<\/jats:italic>: The patients were randomly assigned to two groups: the first included 32 patients under chemotherapy and pamidronate (group I) and the second 30 patients on chemotherapy only (group II). Pamidronate was administered at a monthly dose of 90\u2003mg iv, and the above parameters were evaluated at the beginning of this study and after 1, 3, 6, 9, 12 and 14 months of treatment. <jats:italic>Results<\/jats:italic>: The addition of pamidronate to chemotherapy resulted in a significant reduction of NTx, IL\u20106 and paraprotein from the 3rd month and of \u03b2<jats:sub>2<\/jats:sub>\u2010microglobulin, CRP and pain from the 6th month of treatment. No changes of NTx, IL\u20106, \u03b2<jats:sub>2<\/jats:sub>\u2010microglobulin, CRP or skeletal events were observed in patients of group II, while paraprotein was significantly reduced after 6 months of treatment. The differences in NTx, IL\u20106, paraprotein and \u03b2<jats:sub>2<\/jats:sub>\u2010microglobulin were statistically significant between the two groups. Multivariate analysis revealed a significant correlation between changes of NTx, changes of IL\u20106 in both groups and reduction of pain and paraprotein in group I. <jats:italic>Conclusions<\/jats:italic>: These results suggest that pamidronate may have a synergistic action with chemotherapy in decreasing osteoclastic activity, in reducing markers of myeloma activity and myeloma related pain and in improving the quality of life in patients with MM.<\/jats:p>","DOI":"10.1034\/j.1600-0609.2000.065005331.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T18:49:50Z","timestamp":1047408590000},"page":"331-336","source":"Crossref","is-referenced-by-count":59,"title":["Effect of pamidronate administration on markers of bone turnover and disease activity in multiple myeloma"],"prefix":"10.1111","volume":"65","author":[{"given":"Evangelos","family":"Terpos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Palermos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Tsionos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Anargyrou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Viniou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pantelis","family":"Papassavas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Meletis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xenophon","family":"Yataganas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2001,12,25]]},"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1034%2Fj.1600-0609.2000.065005331.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1034%2Fj.1600-0609.2000.065005331.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1034\/j.1600-0609.2000.065005331.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,29]],"date-time":"2023-10-29T07:56:50Z","timestamp":1698566210000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1034\/j.1600-0609.2000.065005331.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,11]]},"references-count":0,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2000,11]]}},"alternative-id":["10.1034\/j.1600-0609.2000.065005331.x"],"URL":"https:\/\/doi.org\/10.1034\/j.1600-0609.2000.065005331.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,11]]}}}